Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

NCT04127578 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

BIOLOGICAL: LY3884961
DRUG: Methylprednisolone
DRUG: Sirolimus

Sponsor

Prevail Therapeutics

Collaborators

[object Object]